Tobam Grows Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Tobam grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 30.7% in the first quarter, Holdings Channel reports. The firm owned 37,808 shares of the biotechnology company’s stock after purchasing an additional 8,886 shares during the period. Tobam’s holdings in Sarepta Therapeutics were worth $2,413,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Manchester Capital Management LLC grew its position in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 110 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its holdings in shares of Sarepta Therapeutics by 164.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 194 shares during the last quarter. UMB Bank n.a. lifted its holdings in shares of Sarepta Therapeutics by 53.0% during the 1st quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 276 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Sarepta Therapeutics by 95.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 216 shares during the last quarter. Finally, Logan Capital Management Inc. bought a new stake in shares of Sarepta Therapeutics during the 4th quarter worth $61,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on SRPT. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a report on Wednesday, March 19th. Needham & Company LLC reduced their price target on shares of Sarepta Therapeutics from $183.00 to $125.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. JPMorgan Chase & Co. reduced their price target on shares of Sarepta Therapeutics from $169.00 to $84.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 20th. UBS Group lowered their price target on shares of Sarepta Therapeutics from $188.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Finally, Guggenheim cut their price target on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $122.61.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $37.31 on Friday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a one year low of $34.10 and a one year high of $173.25. The company has a 50-day simple moving average of $46.51 and a two-hundred day simple moving average of $87.40. The firm has a market capitalization of $3.67 billion, a PE ratio of 29.85 and a beta of 0.61.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The business had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. During the same period in the prior year, the business posted $0.73 EPS. Sarepta Therapeutics’s revenue for the quarter was up 80.2% on a year-over-year basis. On average, analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.